Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Navigating this part of the market can be tricky, which is why we built StockStory to help you separate the winners from the laggards. Keeping that in mind, here is one Russell 2000 stock that could be a breakout winner and two that may struggle to keep up.
Two Stocks to Sell:
Power Integrations (POWI)
Market Cap: $2.61 billion
A leading supplier of parts for electronics such as home appliances, Power Integrations (NASDAQ:POWI) is a semiconductor designer and developer specializing in products used for high-voltage power conversion.
Why Are We Out on POWI?
- Annual sales declines of 6.4% for the past five years show its products and services struggled to connect with the market during this cycle
- Operating profits fell over the last five years as its sales dropped and it struggled to adjust its fixed costs
- Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 14.1% annually, worse than its revenue
Power Integrations is trading at $46.76 per share, or 28.1x forward P/E. Dive into our free research report to see why there are better opportunities than POWI.
Supernus Pharmaceuticals (SUPN)
Market Cap: $2.44 billion
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.
Why Are We Bearish on SUPN?
- Sales trends were unexciting over the last five years as its 6.5% annual growth was below the typical healthcare company
- Revenue base of $822.8 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 16.5 percentage points
Supernus Pharmaceuticals’s stock price of $42.02 implies a valuation ratio of 2.7x forward price-to-sales. Check out our free in-depth research report to learn more about why SUPN doesn’t pass our bar.
One Stock to Buy:
Bowhead Specialty (BOW)
Market Cap: $1.12 billion
Named after the Arctic bowhead whale known for navigating challenging waters, Bowhead Specialty Holdings (NYSE:BOW) is a specialty insurance company that provides customized coverage for complex and high-risk commercial sectors.
Why Is BOW a Top Pick?
- Net premiums earned surged by 30.3% annually over the past two years, reflecting strong market share gains this cycle
- Expected revenue growth of 19% for the next year suggests its market share will rise
- Annual book value per share growth of 17.6% over the past two years was outstanding, reflecting strong capital accumulation this cycle
At $34.01 per share, Bowhead Specialty trades at 2.2x forward P/B. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.